2-氯-N-甲基乙胺盐酸盐 | 4535-90-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-氯-N-甲基乙胺盐酸盐
• 中文别名: 2-甲基氨乙基氯盐酸盐
• 英文名称: N-methyl-2-chloroethylamine hydrochloride
• 英文别名: 2-(methylamino)ethylchloride hydrochloride；N-Methyl-N-(2-chloroethyl)amine, hydrochloride salt；N-(2-chloroethyl)-N-methylamine hydrochloride；N-methyl-N-(2-chloroethyl)amine hydrochloride；N-(2-chloroethyl)methylamine hydrochloride；2-chloro-N-methylethanamine hydrochloride；(2-chloroethyl)methylamine hydrochloride；1-Chlor-2-methylamino-ethan-hydrochlorid；N-methyl-2-chloroethylammonium chloride；2-chloroethyl(methyl)ammonium chloride；methylchlorethylamine hydrochloride；2-chloro-N-methylethanamine;hydrochloride
• CAS: 4535-90-4
• 化学式: C₃H₈ClN*ClH
• mdl: MFCD00050517
• 分子量: 130.017
• InChiKey: FGSHJLJPYBUBHO-UHFFFAOYSA-N

物化性质

• 熔点：
  89 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.47
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  16.6
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methylaminoethyl chloride HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methylaminoethyl chloride HCl
CAS number: 4535-90-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H8ClN.ClH
Molecular weight: 130.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-N-甲基乙胺盐酸盐 在 sodium azide 作用下， 以 水 为溶剂， 以56%的产率得到1-azido-2-(N-methylamino)ethane
  参考文献：
  名称：

  侧链对叔胺官能化多肽的pH和热响应性的影响

  摘要：

  侧链上的pH的结构影响的系统调查和叔胺官能化聚（热响应性升-谷氨酸）S（TA-的PGs）中的溶液中进行。通过铜（I）催化的叠氮基叔胺与聚（γ-炔丙基-l-谷氨酸）（PPLG）的叠氮化物-炔烃环加成点击反应有效合成了TA-PGs聚合物。进行了比浊法测量，以表征TA-PG在水溶液中的pH和温度诱导的相变，这表明该性质对氮的结构依赖性取代基团和1,2,3-三唑环与侧链中叔胺基团之间的“连接基”。详细地讲，TA-PG的pH响应特性基本上由侧链中N-取代基团的疏水性决定，pH转变点（pH t）随着N-取代基团疏水性的增加而降低，而TA PG的温度响应性受N取代基或“连接基”的影响。具有中等N取代胺基（例如DEA，PR和PD）或支链“连接子”（例如iso-丙烯和2-甲基丙烯基）更可能表达因pH值变化而调整的LCST型相变。这项研究揭示的这些结构-属性关系将有助于开发TA-PG在智能药物输送系统中的应用。©2013

  DOI：

  10.1002/pola.27048
• 作为产物：
  描述：

  N-甲基-2-羟基乙胺 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以68.2%的产率得到2-氯-N-甲基乙胺盐酸盐
  参考文献：
  名称：

  结合定量反应和可逆共价化学的策略，用于顺序合成具有不同序列的序列控制的聚合物

  摘要：

  提出了一种结合定量反应和可逆共价化学的新策略，用于顺序合成一系列具有不同序列的序列控制聚合物。利用丙烯酸酯和硫醇之间的迈克尔加成反应，五元环状二硫代碳酸酯的氨解反应以及溴代马来酰亚胺和硫醇的硫醇取代反应，通过AB，AB'合成了AB-，AB'C-和AB'CD序列的分子。 C和AB'CD分别顺序加入单体。这三个分子的一端均具有呋喃保护的马来酰亚胺基，AB-，AB'C-和AB'CD序列分子的另一端分别为胺，硫醇和蒽基。由于事实上呋喃保护的马来酰亚胺基团可以在高温下通过逆狄尔斯-阿尔德反应有效地转化为马来酰亚胺基团，因此AB-，AB'C-和AB'CD序列化的分子聚合成具有相应序列的受控聚合物序列在120°C下进行。通过这种策略，分子模块的合成不需要分离和纯化，通过添加不同的单体并调节反应条件，可以一锅法合成具有特定序列的序列控制聚合物。

  DOI：

  10.1016/j.polymer.2019.04.017

文献信息

• [EN] AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126731A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为：(I)，其中A、B、R1、X1、X2和W如本文所述。
• Bidentate NHC-Cobalt Catalysts for the Hydrogenation of Hindered Alkenes
  作者：Zeyuan Wei、Yujie Wang、Yibiao Li、Raffaella Ferraccioli、Qiang Liu

  DOI：10.1021/acs.organomet.0c00498

  日期：2020.9.14

  Herein, we report a series of easily accessible bidentate N-heterocyclic carbene (NHC) cobalt catalysts, which enable the hydrogenation of hindered alkenes under mild conditions. The four-coordinated bidentate NHC-Co(II) complexes were characterized by X-ray diffraction, elemental analysis, ESI-HRMS, and magnetic moment measurements, revealing a distorted-tetrahedral geometry and a high-spin configuration

  在此，我们报告了一系列易于获得的双齿N-杂环卡宾（NHC）钴催化剂，该催化剂能够在温和条件下氢化受阻烯烃。通过X射线衍射，元素分析，ESI-HRMS和磁矩测量对四配位的双齿NHC-Co（II）配合物进行表征，揭示了扭曲的四面体几何形状和金属中心的高自旋构型。从容易获得的NHC前体CoCl 2和NaHBEt 3获得的原位形成的催化体系的活性与明确定义的NHC-钴催化剂的活性相同。这突出了该反应系统的潜在用途。
• Phosphorus-31 NMR and chloride ion kinetics of alkylating monoester phosphoramidates
  作者：Kristin M. Fries、Richard F. Borch

  DOI：10.1021/jm00106a014

  日期：1991.2

  conditions. Halide ion kinetics were used to determine the rate of aziridinium ion formation. The solvolysis rates showed the expected dependence upon substitution at the reactive nitrogen; comparison of 4a with phosphoramide mustard (1a) indicated that replacement of the amino group by alkoxy decreased the solvolysis rate by approximately 10-fold. The rate of conversion of starting compound (4a-d) to solvolysis

  31 P NMR光谱用于研究模型生理条件下一系列新型烷基化单酯氨基磷酸酯（4a-d）的溶剂分解动力学。卤离子动力学用于确定叠氮鎓离子形成的速率。溶剂分解速率显示出预期的对反应性氮取代的依赖性。将4a与磷酰胺芥末（1a）进行比较表明，用烷氧基取代氨基会使溶剂分解速率降低约10倍。起始化合物（4a-d）转化为溶剂分解产物的速率基本上等于卤离子的释放速率，这表明叠氮鎓离子是短寿命的中间体。在不存在和存在捕集剂（二甲基二硫代氨基甲酸酯）的情况下进行的1H NMR和31P NMR动力学实验证实，叠氮鎓离子的寿命太短，无法通过NMR观察到。还测试了这些化合物对L1210白血病和B16黑色素瘤细胞的细胞毒性。单烷基化剂4c和4d没有活性，4a具有弱的细胞毒性，而4b的活性与磷酰胺芥菜相当。
• HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES
  申请人：Dolente Cosimo

  公开号：US20110263578A1

  公开（公告）日：2011-10-27

  The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R 1 , R 2 and R 3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及式I所示的杂芳基-环己基-四氮杂苯并[e]氮杂蒽衍生物， 其中R1、R2和R3如本文所述。 根据发明的化合物作为V1a受体的调节剂，尤其是作为V1a受体拮抗剂，它们的制造方法、含有它们的药物组合物以及它们作为药物的使用。本发明的活性化合物作为治疗剂，在周围和中枢条件下对痛经、男性或女性性功能障碍、高血压、慢性心力衰竭、血管加压素的不当分泌、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、孤独症谱系障碍、精神分裂症和侵略性行为有治疗作用。
• Phosphoramidate analogs of 2'-deoxyuridine
  申请人：University of Rochester

  公开号：US05233031A1

  公开（公告）日：1993-08-03

  The present invention provides a series of cytotoxic phosphoramidate analogs of 5-fluoro-2'-deoxyuridine of the general formula (I): ##STR1## wherein R.sup.1 is H, F or (C.sub.1 -C.sub.4)alkyl; R.sup.2 is CH.sub.2 CH.sub.2 X wherein X is Cl, Br, I or p-toluenesulfonyl; R.sup.3 is (C.sub.1 -C.sub.4)alkyl or CH.sub.2 CH.sub.2 X wherein X is Cl, Br, I or p-toluenesulfonyl; or wherein R.sup.2 and R.sup.3, taken together with the N atom, can be a 5- or 6-membered heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or a second ring nitrogen; R.sup.4 is H, one equivalent of a pharmaceutically-acceptable cation or (4,4,6-trimethyltetrahydro-1,3-oxazin-2-yl)ethyl, and the pharmaceutically-acceptable salts thereof.

  本发明提供了一系列细胞毒性的5-氟-2'-脱氧尿嘧啶的磷酰胺类似物，其一般式为(I)：##STR1##其中R.sup.1为H，F或(C.sub.1 -C.sub.4)烷基；R.sup.2为CH.sub.2 CH.sub.2 X，其中X为Cl，Br，I或对甲苯磺酰基；R.sup.3为(C.sub.1 -C.sub.4)烷基或CH.sub.2 CH.sub.2 X，其中X为Cl，Br，I或对甲苯磺酰基；或其中R.sup.2和R.sup.3，与N原子一起，可以是一个5-或6-成员杂环，其为脂肪族的或被一个环氧原子或第二个环氮原子中断的脂肪族；R.sup.4为H，一个等效的药用阳离子或(4,4,6-三甲基四氢-1,3-噁唑啉-2-基)乙基，以及其药用盐。